Market Intel: Glucose Monitor Market Set To Explode As Patients Access Better Devices
The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.
You may also be interested in...
Dexcom received a CE mark for the G7 system in Europe and is awaiting a 510(k) clearance from the US FDA. The G7 is smaller and easier-to-use than the company's G6 CGM and will be more competitive with Abbott's FreeStyle Libre 3 CGM
After more than three years of treating the Tandem Diabetes Care Control-IQ Technology system as moderate-risk class II, the US FDA has made the designation official. The classification will also apply to future similar devices.
After nearly four years of treating the Dexcom glucose monitoring system as moderate-risk class II, the US FDA made the designation official.